﻿<?xml version="1.0" encoding="utf-8"?>
<Item xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Id>612e41bfaa40346ca98897a4</Id>
  <Slug>cenobamate-for-focal-onset-seizures-in-epilepsy-appraisal-consultation-document</Slug>
  <Title>Cenobamate for focal onset seizures in epilepsy: Appraisal consultation document</Title>
  <UpdatedAt>2021-08-31T14:52:33.465Z</UpdatedAt>
  <Source>
    <Id>5e283dc83b5e750642253ccc</Id>
    <Title>National Institute for Health and Care Excellence</Title>
  </Source>
  <Specialities>
    <Speciality>
      <Title>Neurological disorders</Title>
      <Key>793637c7-9615-42b1-905c-4827a6fab04c</Key>
    </Speciality>
  </Specialities>
  <EvidenceType>
    <Title>Media and commentaries</Title>
    <Key>mas_evidence_types:Media%20and%20commentaries</Key>
    <BroaderTitle>Media and commentaries</BroaderTitle>
  </EvidenceType>
  <ShortSummary>In DRAFT guidance, NICE recommends cenobamate as an option for treating focal onset seizures with or without secondary generalised seizures in adults with epilepsy that has not been adequately controlled with at least 2 antiseizure medicines, only if meeting stated criteria.</ShortSummary>
  <Comment>&lt;p&gt;It is only recommended if used as a third-line add-on treatment, and treatment is started and managed in tertiary care.&lt;/p&gt;</Comment>
  <CommentUrl>https://www.medicinesresources.nhs.uk/cenobamate-for-focal-onset-seizures-in-epilepsy-appraisal-consultation-document.html</CommentUrl>
  <ResourceLinks />
  <Url>https://www.nice.org.uk/guidance/indevelopment/gid-ta10661/consultation/html-content-2</Url>
  <PublicationDate>2021-08-31T00:00:00Z</PublicationDate>
  <CreatedAt>2021-08-31T14:50:39.41Z</CreatedAt>
</Item>